{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:23:44Z","timestamp":1791501824737,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"national institute on drug abuse","doi-asserted-by":"publisher","award":["UG1DA015815"],"award-info":[{"award-number":["UG1DA015815"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"national institute on drug abuse","doi-asserted-by":"publisher","award":["UH3DA044831"],"award-info":[{"award-number":["UH3DA044831"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Residential treatment is a common approach for treating opioid use disorder (OUD), however, few studies have directly compared it to outpatient treatment. The objective of this study was to compare OUD outcomes among individuals receiving residential and outpatient treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study used linked data from a state Medicaid program, vital statistics, and the Substance Abuse and Mental Health Services Administration (SAMHSA) Treatment Episodes Dataset (TEDS) to compare OUD-related health outcomes among individuals treated in a residential or outpatient setting between 2014 and 2017. Multivariable Cox proportional hazards and logistic regression models examined the association between treatment setting and outcomes (i.e., opioid overdose, non-overdose opioid-related and all-cause emergency department (ED) visits, hospital admissions, and treatment retention) controlling for patient characteristics, co-morbidities, and use of medications for opioid use disorders (MOUD). Interaction models evaluated how MOUD use modified associations between treatment setting and outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 3293 individuals treated for OUD, 957 (29%) received treatment in a residential facility. MOUD use was higher among those treated as an outpatient (43%) compared to residential (19%). The risk of opioid overdose (aHR 1.39; 95% CI 0.73\u20132.64) or an opioid-related emergency department encounter or admission (aHR 1.02; 95% CI 0.80\u20131.29) did not differ between treatment settings. Independent of setting, MOUD use was associated with a significant reduction in overdose risk (aHR 0.45; 95% CI 0.23\u20130.89). Residential care was associated with greater odds of retention at 6-months (aOR 1.71; 95% CI 1.32\u20132.21) but not 1-year. Residential treatment was only associated with improved retention for individuals not receiving MOUD (6-month aOR 2.05; 95% CI 1.56\u20132.71) with no benefit observed in those who received MOUD (aOR 0.75; 95% CI 0.46\u20131.29; interaction p\u2009=\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Relative to outpatient treatment, residential treatment was not associated with reductions in opioid overdose or opioid-related ED encounters\/hospitalizations. Regardless of setting, MOUD use was associated with a significant reduction in opioid overdose risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00318-1","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:03:58Z","timestamp":1660896238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-773X","authenticated-orcid":false,"given":"Daniel M.","family":"Hartung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Markwardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirbee","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Leichtling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi","family":"Hildebran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi","family":"Ghitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"318_CR1","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2017. https:\/\/www.samhsa.gov\/data\/."},{"key":"318_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","volume":"169","author":"L-T Wu","year":"2016","unstructured":"Wu L-T, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117\u201327.","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 1","key":"318_CR3","first-page":"45","volume":"22","author":"SL Baker","year":"2003","unstructured":"Baker SL, Gastfriend DR. Reliability of multidimensional substance abuse treatment matching: implementing the ASAM Patient Placement Criteria. J Addict Dis. 2003;22(Suppl 1):45\u201360.","journal-title":"J Addict Dis"},{"issue":"sup1","key":"318_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1300\/J069v22S01_06","volume":"22","author":"E Sharon","year":"2004","unstructured":"Sharon E, Krebs C, Turner W, Desai N, Binus G, Penk W, et al. Predictive validity of the ASAM patient placement criteria for hospital utilization. J Addict Dis. 2004;22(sup1):79\u201393.","journal-title":"J Addict Dis"},{"issue":"5","key":"318_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1521-0391.2003.tb00482.x","volume":"12","author":"S Magura","year":"2003","unstructured":"Magura S, Staines G, Kosanke N, Rosenblum A, Foote J, DeLuca A, et al. Predictive validity of the ASAM patient placement criteria for naturalistically matched vs mismatched alcoholism patients. Am J Addict. 2003;12(5):386\u201397.","journal-title":"Am J Addict"},{"issue":"6","key":"318_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.7326\/L18-0685","volume":"170","author":"MR Larochelle","year":"2019","unstructured":"Larochelle MR, Stopka TJ, Xuan Z, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and mortality. Ann Intern Med. 2019;170(6):430\u20131.","journal-title":"Ann Intern Med"},{"key":"318_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357: j1550.","journal-title":"BMJ"},{"key":"318_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1146\/annurev-publhealth-040617-013526","volume":"39","author":"D McCarty","year":"2018","unstructured":"McCarty D, Priest KC, Korthuis PT. Treatment and prevention of opioid use disorder: challenges and opportunities. Annu Rev Public Health. 2018;39:525\u201341.","journal-title":"Annu Rev Public Health"},{"issue":"10182","key":"318_CR9","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","volume":"393","author":"C Blanco","year":"2019","unstructured":"Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760\u201372.","journal-title":"Lancet"},{"key":"318_CR10","unstructured":"Substance Abuse and Mental Health Services Administration. Behavioral Health spending & use accounts 2006\u20132015. HHS Pub. No. (SMA) 19\u20135095. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2019."},{"key":"318_CR11","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2020 national survey on drug use and health: detailed tables, sections 5; [Internet]. Rockville (MD): SAMHSA; 2021."},{"key":"318_CR12","unstructured":"Stewart M, O'Brien P, Shields M, Ma M, Mulvaney D. State residential treatment for behavioral health conditions: regulation and policy environmental scan 2019."},{"issue":"3","key":"318_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1176\/appi.ps.201300242","volume":"65","author":"S Reif","year":"2014","unstructured":"Reif S, George P, Braude L, Dougherty RH, Daniels AS, Ghose SS, et al. Residential treatment for individuals with substance use disorders: assessing the evidence. Psychiatr Serv (Washington, DC). 2014;65(3):301\u201312.","journal-title":"Psychiatr Serv (Washington, DC)"},{"issue":"8","key":"318_CR14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/j.1360-0443.2005.01154.x","volume":"100","author":"W Ling","year":"2005","unstructured":"Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction (Abingdon, England). 2005;100(8):1090\u2013100.","journal-title":"Addiction (Abingdon, England)"},{"key":"318_CR15","first-page":"Cd005031","volume":"9","author":"L Amato","year":"2011","unstructured":"Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011;9:Cd005031.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"318_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jsat.2006.05.019","volume":"31","author":"TL Mark","year":"2006","unstructured":"Mark TL, Vandivort-Warren R, Montejano LB. Factors affecting detoxification readmission: analysis of public sector data from three states. J Subst Abuse Treat. 2006;31(4):439\u201345.","journal-title":"J Subst Abuse Treat"},{"key":"318_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugalcdep.2014.01.006","volume":"137","author":"SE Spear","year":"2014","unstructured":"Spear SE. Reducing readmissions to detoxification: an interorganizational network perspective. Drug Alcohol Depend. 2014;137:76\u201382.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"318_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","volume":"38","author":"R Mojtabai","year":"2019","unstructured":"Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M. Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff. 2019;38(1):14\u201323.","journal-title":"Health Aff"},{"issue":"1","key":"318_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/add.14737","volume":"115","author":"M Stein","year":"2020","unstructured":"Stein M, Herman D, Conti M, Anderson B, Bailey G. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient \u2018detoxification\u2019: a randomized clinical trial. Addiction (Abingdon, England). 2020;115(1):82\u201394.","journal-title":"Addiction (Abingdon, England)"},{"issue":"8","key":"318_CR20","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/add.14964","volume":"115","author":"AY Walley","year":"2020","unstructured":"Walley AY, Lodi S, Li Y, Bernson D, Babakhanlou-Chase H, Land T, et al. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis. Addiction (Abingdon, England). 2020;115(8):1496\u2013508.","journal-title":"Addiction (Abingdon, England)"},{"issue":"12","key":"318_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29676","volume":"3","author":"JR Morgan","year":"2020","unstructured":"Morgan JR, Barocas JA, Murphy SM, Epstein RL, Stein MD, Schackman BR, et al. Comparison of rates of overdose and hospitalization after initiation of medication for opioid use disorder in the inpatient vs outpatient setting. JAMA Netw Open. 2020;3(12): e2029676.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"318_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2): e1920622.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"318_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1001\/jama.2020.8969","volume":"324","author":"T Beetham","year":"2020","unstructured":"Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies offered at residential addiction treatment programs in the United States. JAMA. 2020;324(8):804\u20136.","journal-title":"JAMA"},{"issue":"2","key":"318_CR24","doi-asserted-by":"publisher","first-page":"e1920843-e","DOI":"10.1001\/jamanetworkopen.2019.20843","volume":"3","author":"AS Huhn","year":"2020","unstructured":"Huhn AS, Hobelmann JG, Strickland JC, Oyler GA, Bergeria CL, Umbricht A, et al. Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States. JAMA Netw Open. 2020;3(2):e1920843-e.","journal-title":"JAMA Netw Open"},{"key":"318_CR25","unstructured":"Henry J Kaiser Family Foundation. The opioid epidemic and Medicaid\u2019s role in facilitating access to treatment. www.kff.org\/medicaid\/issue-brief\/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment. Accessed 4 Feb 2021."},{"issue":"14","key":"318_CR26","first-page":"377","volume":"64","author":"MJ Sharp","year":"2015","unstructured":"Sharp MJ, Melnik TA. Poisoning deaths involving opioid analgesics\u2014New York State, 2003\u20132012. MMWR Morb Mortal Wkly Rep. 2015;64(14):377\u201380.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"318_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/j.pain.0000000000002298","volume":"163","author":"SE Hallvik","year":"2022","unstructured":"Hallvik SE, El Ibrahimi S, Johnston K, Geddes J, Leichtling G, Korthuis PT, et al. Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. Pain. 2022;163(1):83\u201390.","journal-title":"Pain"},{"key":"318_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108615","volume":"132","author":"S El Ibrahimi","year":"2022","unstructured":"El Ibrahimi S, Hallvik S, Johnston K, Leichtling G, Korthuis PT, Chan B, et al. Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only. J Subst Abuse Treat. 2022;132: 108615.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"318_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/ADM.0000000000000708","volume":"15","author":"DM Hartung","year":"2021","unstructured":"Hartung DM, Geddes J, Johnston KA, Leichtling G, Hallvik S, Hildebran C, et al. Patterns of prescription opioid use prior to self-reported heroin initiation. J Addict Med. 2021;15(2):130\u20133.","journal-title":"J Addict Med"},{"issue":"11","key":"318_CR30","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1007\/s11606-020-06192-4","volume":"35","author":"DM Hartung","year":"2020","unstructured":"Hartung DM, Johnston KA, Hallvik S, Leichtling G, Geddes J, Hildebran C, et al. Prescription opioid dispensing patterns prior to heroin overdose in a state medicaid program: a case-control study. J Gen Intern Med. 2020;35(11):3188\u201396.","journal-title":"J Gen Intern Med"},{"key":"318_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jsat.2015.01.002","volume":"53","author":"AHS Harris","year":"2015","unstructured":"Harris AHS, Ellerbe L, Phelps TE, Finney JW, Bowe T, Gupta S, et al. Examining the specification validity of the HEDIS quality measures for substance use disorders. J Subst Abuse Treat. 2015;53:16\u201321.","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"318_CR32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","volume":"172","author":"SE Hadland","year":"2018","unstructured":"Hadland SE, Bagley SM, Rodean J, et al. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatr. 2018;172(11):1029.","journal-title":"JAMA Pediatr"},{"issue":"6","key":"318_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","volume":"47","author":"C van Walraven","year":"2009","unstructured":"van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626\u201333.","journal-title":"Med Care"},{"issue":"11","key":"318_CR34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"1","key":"318_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"issue":"7","key":"318_CR36","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MLR.0000000000000735","volume":"55","author":"BJ Moore","year":"2017","unstructured":"Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser Comorbidity Index. Med Care. 2017;55(7):698\u2013705.","journal-title":"Med Care"},{"issue":"2","key":"318_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0387-7604(02)00029-3","volume":"24","author":"V Kalra","year":"2002","unstructured":"Kalra V, Gulati S, Pandey RM, Menon S. West syndrome and other infantile epileptic encephalopathies\u2013Indian hospital experience. Brain Develop. 2002;24(2):130\u20139.","journal-title":"Brain Develop"},{"issue":"8","key":"318_CR38","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/pds.4772","volume":"28","author":"CA Green","year":"2019","unstructured":"Green CA, Perrin NA, Hazlehurst B, Janoff SL, DeVeaugh-Geiss A, Carrell DS, et al. Identifying and classifying opioid-related overdoses: a validation study. Pharmacoepidemiol Drug Saf. 2019;28(8):1127\u201337.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"318_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","volume":"57","author":"RE Clark","year":"2015","unstructured":"Clark RE, Baxter JD, Aweh G, O\u2019Connell E, Fisher WH, Barton BA. Risk Factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75\u201380.","journal-title":"J Subst Abuse Treat"},{"key":"318_CR40","unstructured":"Mee-Lee D, Shulman H, Fishman MJ, Gastfriend DR. The ASAM criteria: treatment criteria for addictive, substance-related, and co-occurring conditions, 3rd edn. Carson City, NV: The Change Companies; 2013. Copyright 2013 by the American Society of Addiction Medicine.; 2013."},{"issue":"11","key":"318_CR41","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1097\/00005650-200111000-00003","volume":"39","author":"SL Wenzel","year":"2001","unstructured":"Wenzel SL, Audrey Burnam M, Koegel P, Morton SC, Miu A, Jinnett KJ, et al. Access to inpatient or residential substance abuse treatment among homeless adults with alcohol or other drug use disorders. Med Care. 2001;39(11):1158\u201369.","journal-title":"Med Care"},{"issue":"9","key":"318_CR42","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(9):979\u201393.","journal-title":"JAMA Psychiat"},{"key":"318_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addbeh.2016.02.030","volume":"58","author":"GJ Stahler","year":"2016","unstructured":"Stahler GJ, Mennis J, DuCette JP. Residential and outpatient treatment completion for substance use disorders in the U.S.: moderation analysis by demographics and drug of choice. Addict Behav. 2016;58:129\u201335.","journal-title":"Addict Behav"},{"key":"318_CR44","unstructured":"Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment episode data set (TEDS): 2019. admissions to and discharges from publicly funded substance use treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2021."},{"key":"318_CR45","unstructured":"Analysis of Oregon\u2019s publicly funded substance abuse treatment system: report and findings for senate bill 1041. Oregon Criminal Justice Commission. 2019."},{"key":"318_CR46","unstructured":"2019-2020 NSDUH State Estimates Of Substance Use And Mental Disorders. December 29, 2021. https:\/\/www.samhsa.gov\/data\/report\/2019-2020-nsduh-state-prevalence-estimates."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00318-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00318-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00318-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:13:50Z","timestamp":1660896830000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00318-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00318-1","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"7 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed by the OHSU IRB and is considered non-human subjects research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}